Lab Location: AKH, Level 8, G1.12
E-Mail: daniela.kandioler@meduniwien.ac.at
Phone: +43 1 40400 56210/68480
Website: www.p53.at
Over- and undertreatment is the main clinical challenge of today’s cancer treatment. To significantly advance cancer survival, we have to identify the most effective treatment for the individual patient.
We claim that the p53 gene could be used as a global predictor for response and resistance to chemotherapy.
The major goal of our projects is to pave the way for routine clinical application of this marker.
Response Prediction
Fifty percent of patients currently do not benefit from standard cancer treatment. P53 is crucially involved in pathways determining cell death in response to treatment, and is at the same time the most frequently mutated gene in human cancer. Thus, a defect in the p53 pathway causes resistance to chemotherapy and radiation.
During the last years, we could consistently demonstrate the relation between the p53 genotype and response to cancer therapies in different tumours.
Prognosis
Prognostic factors influence treatment decisions, estimating the likelihood of recovering from disease or the chance of the disease coming back.
In cancer patients, the most important, clinically used prognostic factor is the involvement of lymph nodes.
Lymph nodes that are staged microscopically as tumour free can be analysed more precisely using molecular techniques. A p53 mutation of the primary cancer can serve as marker to search for micrometastases in lymph nodes.
Methodological Research
Due to uncoordinated application of different, insensitive p53 analysis methods and lack of standards, the literature appears to be inconsistent concerning the prognostic and predictive value of p53. Our research projects are based on complete sequencing of the p53 gene and therefore provide most sensitive and specific information concerning the p53 genotype.
<b>Partner</b> | <b>Title</b> |
Christine Brostjan, MUW, Dept. of Surgery, Research Laboratories | Analysis of Angiogenesis Parameters in the context of the PART-1 Trial |
Christine Mannhalter, MUW, Department of Laboratory Medicine | Genetic variants predicting 5-FU toxicity |
Rainer Schmid, MUW, Department of Radiotherapy | Radiotherapy in the context of the PART1 trial |
Christiane Kulinna-Cosentini, MUW, Department of Radiology | Advanced MRT Protocol and CT Protocol for rectal cancer |
Christos Perisanidis, MUW, Dept. of Cranio-, Maxillofacial and Oral Surgery | p53 genotype in oral cancer |
Bettina Grasl-Kraupp, MUW, Institute of Cancer Research | Hepatocarcinogenesis |
Magali Olivier, International Agency for Research on Cancer,(IARC/CIRC), Lyon, France | p53 mutation database |